Immatics Set to Present Innovative Cancer Therapies at SIC 2024

Immatics' Presentations at Major Oncology Conference

Houston, Texas and Tuebingen, Germany – Immatics N.V. (NASDAQ: IMTX), a pioneering biopharmaceutical company focused on developing T cell-redirecting cancer immunotherapies, has announced a series of impactful oral and poster presentations at the upcoming Society for Immunotherapy of Cancer Annual Meeting. Set to take place in early November, this event promises to shed light on the advancements in cancer treatment technologies aimed at enhancing patient outcomes.

Event Details and Abstract Availability

Anticipation is building for the 39th Annual Meeting of the Society for Immunotherapy of Cancer, where full abstracts related to the presentations will be made public on November 5. This meeting is a vital platform for showcasing innovative research and clinical findings within the oncology community, and Immatics is thrilled to contribute significantly.

Oral Presentation Highlights

The oral presentations are slated for November 8 and 9, featuring key research on new therapies designed to boost anti-tumor activity:

• Date / Time: November 8 / 3:50 – 5:25 pm CST
  Session: Oral Abstract Session 1
  Abstract Number: 687
  Title: ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients
  Presenter: Martin Wermke, M.D. (University Hospital Dresden, Germany)
• Date / Time: November 9 / 12:30 PM - 1:30 pm CST
  Session: Rapid Oral - Clinical 2
  Abstract Number: 661
  Title: Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME
  Presenter: Dejka M. Araujo, M.D. (MD Anderson Cancer Center)

Poster Presentation Details

Posters will also be presented on November 8 and 9, showcasing advanced methodologies and strategies in cancer therapy:

• Date: November 8
  Poster Number: 355
  Title: An approach to bridging starting materials to monitor T cell persistence in adoptive T cell therapy
  Presenter: Jourdan Andersson, Ph.D. (Immatics)
• Date: November 9
  Poster Number: 226
  Title: An effective donor screening program for manufacturing allogeneic ?? T cell products
  Presenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics)
• Date: November 9
  Poster Number: 228
  Title: Optimizing and streamlining the manufacturing of V?9V?2 ?? T cells for allogeneic therapy
  Presenter: Pooja Mehta, Ph.D. (Immatics)
• Date: November 9
  Abstract Number: 360
  Title: Combination of a TCR-engineered autologous PRAME-targeting T cell therapy with a PRAME-encoding mRNA for the treatment of solid tumors
  Presenter: Fabian Brunk, Ph.D. (Immatics)
• Date: November 9
  Poster Number: 372
  Title: TCR-engineered T cells exhibit enhanced persistence and serial killing ability when armored with membrane-bound IL-15
  Presenter: Justin Gunesch, Ph.D. (Immatics)

Understanding IMA203 and PRAME Targeting

The ACTengine® IMA203 T cells focus on a specific peptide associated with PRAME, a protein often found across numerous solid cancers. This targeting approach allows for a potent response against tumors that share these malignant markers. Immatics’ proprietary technology enhances the reliability and efficacy of its therapies, making significant strides in the realm of cancer treatment.

About Immatics

Bringing together extensive knowledge and cutting-edge technology, Immatics aims to craft precise T cell responses designed to combat cancer effectively. Their robust pipeline includes Adoptive Cell Therapies and TCR Bispecifics, alongside diverse partnerships in the pharmaceutical arena, demonstrating their commitment to transforming cancer treatment.

Company Engagement and Further Information

To stay informed regarding ongoing innovations, Immatics utilizes its website as a primary communication channel for announcing critical updates. They also maintain active social media profiles, enhancing transparency and engagement with the community.

Frequently Asked Questions

What is the significance of the Society for Immunotherapy of Cancer Annual Meeting?

The meeting serves as a key platform for researchers and developers to share findings and advancements in cancer immunotherapy and treatment options.

How does the IMA203 treatment work?

IMA203 utilizes T cell receptors specifically engineered to target the PRAME antigen present in many solid tumors, aiming to enhance the body's natural immune response against cancer.

Who are the presenters for Immatics' upcoming sessions?

Presenters include leading professionals from renowned institutions, such as University Hospital Dresden and MD Anderson Cancer Center, showcasing high-level research.

What technologies does Immatics leverage in its therapies?

Immatics employs unique platforms like XPRESIDENT® for target discovery and XCEPTOR® for T cell receptor engineering, ensuring advanced therapeutic strategies.

How can I reach Immatics for further inquiries?

For more information, you can contact Immatics' media or investor relations via the provided email addresses yielding prompt responses.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.